|
|
Vaccine Detail
|
SCB-2019 |
| Vaccine Information |
- Vaccine Name: SCB-2019
- Target Pathogen: SARS-CoV-2
- Target Disease: COVID-19
- Manufacturer: Clover Biopharmaceuticals, GSK, Dynavax
- Vaccine Ontology ID: VO_0004994
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Baboon Response
- Immune Response: . SCB-2019 with no adjuvant elicited minimal immune responses (three seroconversions by day 50), but SCB-2019 with fixed doses of either AS03 or CpG/Alum adjuvants induced high titres and seroconversion rates of binding and neutralising antibodies in both younger and older adults (Richmond et al., 2021)
- Side Effects: Most local adverse events were mild injection-site pain (Richmond et al., 2021)
|
| References |
Richmond et al., 2021: Peter Richmond 1, Lara Hatchuel 2, Min Dong 3, Brenda Ma 3, Branda Hu 3, Igor Smolenov 3, Ping Li 3, Peng Liang 3, Htay Htay Han 3, Joshua Liang 3, Ralf Clemens 4. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. . 2021; ; . [PubMed: 33524311].
|
|
